Cargando…

SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population

Reliable antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to uncover the population-wide spread of coronavirus disease 2019 (COVID-19), which is critical for making informed healthcare and economic decisions. Here we review different types of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogl, Thomas, Leviatan, Sigal, Segal, Eran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834181/
https://www.ncbi.nlm.nih.gov/pubmed/33521694
http://dx.doi.org/10.1016/j.xcrm.2021.100191
_version_ 1783642223402811392
author Vogl, Thomas
Leviatan, Sigal
Segal, Eran
author_facet Vogl, Thomas
Leviatan, Sigal
Segal, Eran
author_sort Vogl, Thomas
collection PubMed
description Reliable antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to uncover the population-wide spread of coronavirus disease 2019 (COVID-19), which is critical for making informed healthcare and economic decisions. Here we review different types of antibody tests available for SARS-CoV-2 and their application for population-scale testing. Biases because of varying test accuracy, results of ongoing large-scale serological studies, and use of antibody testing for monitoring development of herd immunity are summarized. Although current SARS-CoV-2 antibody testing efforts have generated valuable insights, the accuracy of serological tests and the selection criteria for the tested cohorts need to be evaluated carefully.
format Online
Article
Text
id pubmed-7834181
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78341812021-01-26 SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population Vogl, Thomas Leviatan, Sigal Segal, Eran Cell Rep Med Perspective Reliable antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to uncover the population-wide spread of coronavirus disease 2019 (COVID-19), which is critical for making informed healthcare and economic decisions. Here we review different types of antibody tests available for SARS-CoV-2 and their application for population-scale testing. Biases because of varying test accuracy, results of ongoing large-scale serological studies, and use of antibody testing for monitoring development of herd immunity are summarized. Although current SARS-CoV-2 antibody testing efforts have generated valuable insights, the accuracy of serological tests and the selection criteria for the tested cohorts need to be evaluated carefully. Elsevier 2021-01-14 /pmc/articles/PMC7834181/ /pubmed/33521694 http://dx.doi.org/10.1016/j.xcrm.2021.100191 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Vogl, Thomas
Leviatan, Sigal
Segal, Eran
SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title_full SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title_fullStr SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title_full_unstemmed SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title_short SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
title_sort sars-cov-2 antibody testing for estimating covid-19 prevalence in the population
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834181/
https://www.ncbi.nlm.nih.gov/pubmed/33521694
http://dx.doi.org/10.1016/j.xcrm.2021.100191
work_keys_str_mv AT voglthomas sarscov2antibodytestingforestimatingcovid19prevalenceinthepopulation
AT leviatansigal sarscov2antibodytestingforestimatingcovid19prevalenceinthepopulation
AT segaleran sarscov2antibodytestingforestimatingcovid19prevalenceinthepopulation